Yosuke Okada Selected Research

Hypothyroidism

1/2021	[A Case of Thyroid Dysfunction and Isolated Adrenocorticotropin Deficiency after Nivolumab Therapy for Malignant Melanoma].
9/2003	[A case of Hypothyroid Graves' disease with extremely high titers of TSAb].
12/2002	[A case of hypothyroidism due to hashimoto disease that presented elevations of free T3 and free T4 by thyroid hormone autoantibodies].

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Yosuke Okada Research Topics

Disease

60	Type 2 Diabetes Mellitus (MODY) 04/2022 - 06/2005
22	Hypoglycemia (Reactive Hypoglycemia) 01/2022 - 02/2006
15	Atherosclerosis 09/2021 - 05/2003
14	Neoplasms (Cancer) 03/2022 - 07/2004
12	Hyperglycemia 01/2021 - 06/2005
12	Osteoporosis 01/2018 - 06/2003
10	Bone Resorption 01/2021 - 08/2002
9	Cardiovascular Diseases (Cardiovascular Disease) 01/2021 - 10/2017
9	Hypercalcemia (Milk Alkali Syndrome) 10/2020 - 06/2003
8	Diabetes Mellitus 09/2021 - 06/2006
7	Autoimmune Diseases (Autoimmune Disease) 02/2021 - 01/2004
7	Vascular Calcification 01/2019 - 08/2006
6	Hyperemia 02/2022 - 01/2020
6	Insulin Resistance 01/2019 - 01/2006
6	Graves Disease (Basedow Disease) 01/2017 - 01/2014
5	Body Weight (Weight, Body) 01/2022 - 10/2008
4	Neoplasm Metastasis (Metastasis) 03/2022 - 01/2012
4	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 03/2021 - 01/2015
4	Hypertension (High Blood Pressure) 01/2021 - 07/2012
4	Insulinoma 05/2020 - 02/2006
4	Bone Fractures (Bone Fracture) 11/2019 - 06/2003
4	Hypophosphatemia 02/2019 - 01/2012
3	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 02/2022 - 04/2018
3	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2022 - 01/2021
3	Multiple Myeloma 01/2022 - 01/2019
3	Glucose Intolerance 01/2022 - 10/2008
3	Diabetic Angiopathies (Diabetic Angiopathy) 04/2021 - 12/2006
3	Heart Failure 01/2021 - 04/2017
3	Thyroiditis 01/2021 - 09/2003
3	Hypothyroidism 01/2021 - 12/2002
3	Osteomalacia 10/2020 - 01/2012
3	Hyperparathyroidism 10/2020 - 04/2004
3	Chronic Renal Insufficiency 01/2020 - 07/2012
3	Hyperinsulinism (Hyperinsulinemia) 01/2018 - 06/2005
2	Hepatoblastoma 03/2022 - 03/2022
2	Leukemia 03/2022 - 02/2022
2	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 02/2022 - 01/2022
2	Systemic Lupus Erythematosus (Libman-Sacks Disease) 01/2022 - 01/2020
2	Melanoma (Melanoma, Malignant) 01/2022 - 01/2021
2	Overweight 01/2022 - 01/2006
2	Disease Progression 01/2022 - 01/2012

Drug/Important Bio-Agent (IBA)

45	Glucose (Dextrose)FDA LinkGeneric 04/2022 - 01/2006
17	Blood Glucose (Blood Sugar)IBA 01/2022 - 01/2013
12	Diphosphonates (Bisphosphonates)IBA 11/2016 - 11/2002
11	Insulin (Novolin)FDA Link 04/2022 - 06/2005
10	Sodium-Glucose Transporter 2 InhibitorsIBA 09/2021 - 01/2017
9	GlucocorticoidsIBA 11/2016 - 06/2003
8	Prednisolone (Predate)FDA LinkGeneric 01/2022 - 11/2008
8	Hypoglycemic Agents (Hypoglycemics)IBA 01/2022 - 12/2012
7	Hemoglobins (Hemoglobin)IBA 04/2022 - 05/2014
6	Vitamin D FDA LinkGeneric 02/2022 - 12/2012
6	Pharmaceutical PreparationsIBA 01/2022 - 06/2005
6	AlbuminsIBA 04/2021 - 12/2006
6	Sodium-Glucose Transport ProteinsIBA 01/2021 - 04/2017
6	CalciumIBA 02/2019 - 07/2004
6	voglibose (Basen)IBA 06/2018 - 02/2006
6	LipidsIBA 04/2018 - 10/2008
6	CytokinesIBA 01/2018 - 07/2004
5	6- ((4- ethylphenyl)methyl)- 3',4',5',6'- tetrahydro- 6'- (hydroxymethyl)spiro(isobenzofuran- 1(3H),2'- (2H)pyran)- 3',4',5'- triolIBA 09/2021 - 10/2017
5	SodiumIBA 09/2021 - 01/2014
5	CholesterolIBA 01/2021 - 12/2006
5	empagliflozinIBA 01/2021 - 04/2017
5	oxidized low density lipoproteinIBA 03/2018 - 05/2003
4	Triglycerides (Triacylglycerol)IBA 04/2022 - 12/2006
4	hydroxide ionIBA 02/2022 - 08/2002
4	alogliptinIBA 01/2021 - 07/2013
4	Metformin (Glucophage)FDA LinkGeneric 01/2021 - 09/2013
4	Dipeptidyl-Peptidase IV InhibitorsIBA 01/2021 - 02/2017
4	Glycated Hemoglobin (Glycosylated Hemoglobin)IBA 01/2021 - 12/2016
4	Parathyroid Hormone (Parathormone)IBA 10/2020 - 04/2004
4	Fibroblast Growth Factor-23IBA 10/2020 - 01/2012
4	Sitagliptin Phosphate (Januvia)FDA Link 01/2020 - 05/2014
4	LinagliptinIBA 06/2018 - 11/2016
4	alfacalcidolIBA 11/2016 - 01/2004
4	Etidronic Acid (HEDP)FDA LinkGeneric 01/2012 - 01/2004
3	CreatinineIBA 04/2021 - 01/2012
3	AutoantibodiesIBA 02/2021 - 12/2002
3	AntigensIBA 01/2021 - 08/2002
3	Thyroxine (Levothyroxine)FDA LinkGeneric 01/2021 - 03/2015
3	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 01/2021 - 09/2013
3	Thyrotropin (Thyroid-Stimulating Hormone)FDA Link 04/2020 - 03/2015
3	dapagliflozinIBA 01/2020 - 06/2016
3	Rituximab (Mabthera)FDA Link 01/2020 - 01/2015
3	ipragliflozinIBA 01/2020 - 01/2019
3	Interleukin-6 (Interleukin 6)IBA 01/2019 - 11/2007
3	Glucagon-Like Peptide 1 (GLP 1)IBA 01/2018 - 05/2014
3	Octreotide (Sandostatin)FDA LinkGeneric 01/2017 - 02/2006
3	AdiponectinIBA 07/2012 - 01/2006
3	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 03/2008 - 06/2005
2	Methylprednisolone FDA LinkGeneric 03/2022 - 01/2018
2	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2022 - 06/2006
2	AntibodiesIBA 01/2022 - 01/2018
2	Biological ProductsIBA 01/2022 - 02/2006

Therapy/Procedure

31	Therapeutics 01/2022 - 01/2004
10	Glycemic Control 02/2019 - 06/2006
5	Aftercare (After-Treatment) 04/2020 - 01/2014
4	Drug Therapy (Chemotherapy) 03/2022 - 07/2004
3	Transplantation 02/2022 - 01/2021
3	Cell Transplantation 01/2022 - 01/2022
3	Hematopoietic Stem Cell Transplantation 01/2022 - 01/2022